Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC

NCT03672305 | Unknown Early Phase 1

• 1 other identifier: JGZNO1
• Study Type: interventional
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

Title: Single-center, open clinical study on the efficacy and safety of c-Met/PD-L1 T cell injection in the treatment of primary hepatocellular carcinoma Stage: Phase I clinical trial Purpose: To evaluate the efficacy and safety of c-Met/PD-L1 CAR-T cells in patients with primary hepatocellular carcinoma Object: patients with primary hepatocellular carcinoma Sample size: 50 cases Number of centres：1 Study design: CT, MRI, PET and blood biochemical tests were performed before treatment to evaluate the state of HCC. Peripheral blood of the patient was extracted and PBMC was isolated. CAR-T cells were obtained by tranducing PBMC with c-Met/PD-L1 CAR lentivirus, and the proliferation capacity and immune phenotype of the cells were tested. After passing the inspection, the cells were re-injected into the patient three times. The efficacy and safety of c-Met/PD-L1 CAR-T cells was assessed respectively at 4 week, 12 week, 24 week and 48 week after treatment. Trial product: c-Met/PD-L1 CAR-T cells Course of treatment: 3 days for a course of treatment, only one course of treatment. A second course is given as appropriate if the treatment is beneficial to the patient.

Conditions

Primary Hepatocellular Carcinoma

Outcome Measures

Primary Outcomes (1)

• The efficacy of c-Met/PD-L1 CAR-T cells in the treatment of HCC

  assessing the efficacy of c-Met/PD-L1 CAR-T cells through overall survival

  6 months after treatment

Secondary Outcomes (2)

• the incidence of treatment-emergent adverse events of c-Met/PD-L1 T cell injection in the treatment of HCC

  6 months after treatment

• The amplification and persistence of c-Met/PD-L1 CAR-T cell in the subjects varied with time

  6 months after treatment

Study Arms (1)

c-Met/PD-L1 CAR-T cells treating group

OTHER

Intervention Name:c-Met/PD-L1 CAR-T cell injection dosage form: injection dosage:The backtransfusion dose (recommended dose: 2 \* 10\^6/kg) was determined by the investigator based on the subject's own/disease condition and in vitro preparation.

Biological: c-Met/PD-L1 CAR-T cell injection

Interventions

c-Met/PD-L1 CAR-T cell injection BIOLOGICAL

injection content:c-Met/PD-L1 CAR-T cell Infusion way:Steady intravenous drip in 15 to 30 minutes

c-Met/PD-L1 CAR-T cells treating group

Eligibility Criteria

• Age: 18 Years - 70 Years
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female patients aged 18 to 70 years (including 18 and 70 years);
• Immune histochemistry detection was confirmed as c-met positive ; hepatocellular carcinoma, and the patient has no effective treatment at present
• Liver tissue type: non-diffuse hepatocellular carcinoma, no extra hepatic metastasis or portal vein infiltration;
• Cirrhosis of the liver: child-pugh A grade or child-pugh B grade, child-pugh-turcotte score \<7;
• Routine blood test: white blood cell count (WBC) or 3 \* 10\^9/L, lymphocyte percentage (LY) 15% or higher, hemoglobin (Hb), 90g/L or higher, prothrombin time (PT), international standardization ratio (INR) 1.7 or less, or prothrombin time (PT) extend the 4 s or less, lymphocyte acuity 0.8 \* 10\^9/L;
• The main tissues and organs of the patients are functioning well (if the organs do not meet the following standards, but the researchers believe that the diseases themselves can be included):
• Hepatic and pancreatic functions: alanine aminotransferase/aspartate aminotransferase (ALT/AST) is 5 times of normal value, total bilirubin (TBiL) is 3.0mg/dL, albumin (ALB) is 35g/L, serum lipase is 1.5 times of normal value, and serum amylase is 1.5 times of normal value. Renal function: creatinine \<2 ULN
• Lung function: indoor oxygen saturation greater than or equal to 95% (without oxygen inhalation)
• Cardiac function: LVEF is greater than or equal to 40%
• The absolute number of neutrophils is greater than or equal to 0.75 \* 10\^9/L, and platelets are greater than or equal to 50 \* 10\^9/L
• ECOG score 0-1 or Karnofsky performance status (card score) (KPS) is greater than 60, and the expected survival time is greater than or equal to 12 weeks;
• There are adequate venipuncture or venous sampling channels and no contraindications for lymphocyte separation;
• No anti-tumor therapy, including chemotherapy, radiotherapy and immunotherapy (such as immunosuppressive drugs), was received within 4 weeks before enrollment, and the toxicity response of previous treatment was restored to level 1 or less (except for low-level toxicity such as hair loss);
• Female subjects of reproductive age must have negative serum or urine pregnancy test during screening, and male and female patients agree to take effective contraceptive measures during the trial;
• There were no other serious complications;

You may not qualify if:

• Women during pregnancy (positive urine/blood pregnancy test) or lactation; A male or female who has a plan to conceive within the last 1 year; Effective contraceptive (condom or birth control pill, etc.) cannot be guaranteed for 1 year after enrollment;
• The patients had uncontrollable infection within 4 weeks before enrollment. However, prophylactic antibiotics, antiviral and antifungal infection treatment are allowed; Active hepatitis b hepatitis c; People infected with human immunodeficiency virus (HIV);
• Suffering from severe autoimmune disease or immunodeficiency disease;
• The patient is allergic to large molecular biological drugs such as antibodies or cytokines;
• The patient who has mentally ill;
• The patient has substance abuse/addiction;
• The patient who has a history of hepatocellular carcinoma;
• Having severe peptic ulcer or bleeding;
• A patient who receives an organ transplant or waits for one;
• Patients requiring anticoagulation (e.g., warfarin or heparin);
• Patients requiring long-term antiplatelet therapy (aspirin \> 300 mg/d; Clopidogrel dose \> 75 mg/d);
• Organ failure patient:
• Cardiac function: grade 3 or above according to the New York heart association (NYHA) standard
• Liver function: C level above, according to child-pugh standard
• Chronic kidney disease (CKD) stage 4 or above; Renal insufficiency or above

Sponsors & Collaborators

• The Second Hospital of Nanjing Medical University: lead

Related Publications (16)

• Li YW, Yang FC, Lu HQ, Zhang JS. Hepatocellular carcinoma and hepatitis B surface protein. World J Gastroenterol. 2016 Feb 14;22(6):1943-52. doi: 10.3748/wjg.v22.i6.1943.

  PMID: 26877602 BACKGROUND

• McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015 May;19(2):223-38. doi: 10.1016/j.cld.2015.01.001. Epub 2015 Feb 26.

  PMID: 25921660 BACKGROUND

• Tagliamonte M, Petrizzo A, Tornesello ML, Ciliberto G, Buonaguro FM, Buonaguro L. Combinatorial immunotherapy strategies for hepatocellular carcinoma. Curr Opin Immunol. 2016 Apr;39:103-13. doi: 10.1016/j.coi.2016.01.005. Epub 2016 Feb 4.

  PMID: 26851637 BACKGROUND

• Kenderian SS, Ruella M, Gill S, Kalos M. Chimeric antigen receptor T-cell therapy to target hematologic malignancies. Cancer Res. 2014 Nov 15;74(22):6383-9. doi: 10.1158/0008-5472.CAN-14-1530. Epub 2014 Nov 4.

  PMID: 25371415 BACKGROUND

• Pico de Coana Y, Choudhury A, Kiessling R. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends Mol Med. 2015 Aug;21(8):482-91. doi: 10.1016/j.molmed.2015.05.005. Epub 2015 Jun 16.

  PMID: 26091825 BACKGROUND

• Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011 Nov 3;118(18):4817-28. doi: 10.1182/blood-2011-04-348540. Epub 2011 Aug 17.

  PMID: 21849486 BACKGROUND

• Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235-71. doi: 10.1146/annurev-immunol-031210-101324.

  PMID: 21219185 BACKGROUND

• Dotti G, Savoldo B, Brenner M. Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther. 2009 Nov;20(11):1229-39. doi: 10.1089/hum.2009.142.

  PMID: 19702437 BACKGROUND

• Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 2011 Nov;29(11):550-7. doi: 10.1016/j.tibtech.2011.04.009. Epub 2011 Jun 12.

  PMID: 21663987 BACKGROUND

• Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012 Mar 22;119(12):2709-20. doi: 10.1182/blood-2011-10-384388. Epub 2011 Dec 8.

  PMID: 22160384 BACKGROUND

• Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.

  PMID: 24553386 BACKGROUND

• Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29.

  PMID: 24876563 BACKGROUND

• Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014 Apr 24;123(17):2625-35. doi: 10.1182/blood-2013-11-492231. Epub 2014 Feb 27.

  PMID: 24578504 BACKGROUND

• Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014 Mar-Apr;20(2):119-22. doi: 10.1097/PPO.0000000000000035.

  PMID: 24667956 BACKGROUND

• Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available.

  PMID: 7165009 BACKGROUND

• Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016 Jun 30;127(26):3321-30. doi: 10.1182/blood-2016-04-703751. Epub 2016 May 20.

  PMID: 27207799 BACKGROUND

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Study Officials

• Guozhong Ji, archiater

  Second affiliated hospital of nanjing medical university

  STUDY CHAIR

Central Study Contacts

Guozhong Ji, archiater

CONTACT

+86-13951031818; J58430@njmu.edu.cn

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: September 7, 2018
• First Posted: September 14, 2018
• Study Start: October 1, 2018
• Primary Completion: October 30, 2019
• Study Completion: October 30, 2019
• Last Updated: September 18, 2018

Record last verified: 2018-09